-
公开(公告)号：US07985748B2
公开(公告)日：2011-07-26
申请号：US12722879
申请日：2010-03-12
Applicant: Kevin D. McCormick , Christopher W. Boyce , Neng-Yang Shih , Robert G. Aslanian , Pietro Mangiaracina , Manuel de Lera Ruiz , Younong Yu , Purakkattle Biju , Chia-Yu Huang , Bo Liang , Ruiyan Liu , Rong-Qiang Liu , Lisa Guise-Zawacki
Inventor： Kevin D. McCormick , Christopher W. Boyce , Neng-Yang Shih , Robert G. Aslanian , Pietro Mangiaracina , Manuel de Lera Ruiz , Younong Yu , Purakkattle Biju , Chia-Yu Huang , Bo Liang , Ruiyan Liu , Rong-Qiang Liu , Lisa Guise-Zawacki
IPC: C07D413/06 , A61K31/538
CPC classification number: C07D413/06 , C07D403/06 , C07D413/04 , C07D413/14 , C07D417/06 , C07D471/04 , C07D487/04 , C07D498/04
Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
Abstract translation: 在其许多实施方案中，本发明涉及可用作α2C肾上腺素能受体激动剂的新一类苯基吗啉和苯硫基吗啉化合物，含有该化合物的药物组合物，以及治疗，预防，抑制或改善一种或多种与 α2C肾上腺素能受体激动剂，使用这些化合物或药物组合物。
-
公开(公告)号：US20070093477A1
公开(公告)日：2007-04-26
申请号：US11508467
申请日：2006-08-23
Applicant: Kevin McCormick , Christopher Boyce , Neng-Yang Shih , Robert Aslanian , Pietro Mangiaracina , Manuel de Lera Ruiz , Younong Yu , Purakkattle Biju , Chia-Yu Huang , Bo Liang , Ruiyan Liu , Rong-Qiang Liu , Lisa Guise-Zawacki
Inventor： Kevin McCormick , Christopher Boyce , Neng-Yang Shih , Robert Aslanian , Pietro Mangiaracina , Manuel de Lera Ruiz , Younong Yu , Purakkattle Biju , Chia-Yu Huang , Bo Liang , Ruiyan Liu , Rong-Qiang Liu , Lisa Guise-Zawacki
IPC: A61K31/5415 , A61K31/538 , A61K31/498 , C07D413/02 , C07D417/02
CPC classification number: C07D413/06 , C07D403/06 , C07D413/04 , C07D413/14 , C07D417/06 , C07D471/04 , C07D487/04 , C07D498/04
Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
Abstract translation: 在其许多实施方案中，本发明涉及可用作α2C肾上腺素能受体激动剂的新型苯基吗啉和苯硫基吗啉化合物，含有该化合物的药物组合物，以及治疗，预防，抑制或改善一种或多种与 α2C肾上腺素能受体激动剂，使用这些化合物或药物组合物。
-
公开(公告)号：US07803828B2
公开(公告)日：2010-09-28
申请号：US11508458
申请日：2006-08-23
Applicant: Kevin D. McCormick , Christopher W. Boyce , Robert G. Aslanian , Neng-Yang Shih , Salem Fevrier , Pietro Mangiaracina , Chia-Yu Huang , Bo Liang , Rong-Qiang Liu , Huagang Lu
Inventor： Kevin D. McCormick , Christopher W. Boyce , Robert G. Aslanian , Neng-Yang Shih , Salem Fevrier , Pietro Mangiaracina , Chia-Yu Huang , Bo Liang , Rong-Qiang Liu , Huagang Lu
IPC: A01N43/50 , C07D233/00
CPC classification number: C07D403/02 , C07D401/06 , C07D403/06
Abstract: In its many embodiments, the present invention provides a novel class of indolines as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
Abstract translation: 在其许多实施方案中，本发明提供了作为α2C肾上腺素能受体激动剂抑制剂的新一类中和体，制备此类化合物的方法，含有一种或多种此类化合物的药物组合物，制备包含一种或多种此类化合物的药物制剂的方法，以及 使用这些化合物或药物组合物治疗，预防，抑制或改善与α2C肾上腺素能受体相关的一种或多种病症的方法。
-
公开(公告)号：US20080039439A1
公开(公告)日：2008-02-14
申请号：US11705673
申请日：2007-02-13
Applicant: Kevin McCormick , Christopher Boyce , Neng-Yang Shih , Chia-Yu Huang , Robert Aslanian , Salem Fevrier , Bo Liang , Rong-qiang Liu , Ruiyan Liu , Pietro Mangiaracina , Manuel de Lera Ruiz , Younong Yu , Lisa Guise-Zawacki , Junying Zheng
Inventor： Kevin McCormick , Christopher Boyce , Neng-Yang Shih , Chia-Yu Huang , Robert Aslanian , Salem Fevrier , Bo Liang , Rong-qiang Liu , Ruiyan Liu , Pietro Mangiaracina , Manuel de Lera Ruiz , Younong Yu , Lisa Guise-Zawacki , Junying Zheng
IPC: A61K31/535 , A61K31/502 , A61K31/54 , A61K31/553 , A61P1/00 , A61P25/00 , A61P37/00 , A61P9/00 , C07D241/36 , C07D279/06 , C07D498/04 , C12N5/06
CPC classification number: C07D413/14 , C07D241/36 , C07D279/06 , C07D403/06 , C07D413/06 , C07D417/06 , C07D417/14 , C07D471/04 , C07D498/04
Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
Abstract translation: 在其许多实施方案中，本发明涉及可用作α2C肾上腺素能受体激动剂的新型苯基吗啉和苯硫基吗啉化合物，含有该化合物的药物组合物，以及治疗，预防，抑制或改善一种或多种与 α2C肾上腺素能受体激动剂，使用这些化合物或药物组合物。
-
公开(公告)号：US20080027100A1
公开(公告)日：2008-01-31
申请号：US11705683
申请日：2007-02-13
Applicant: Kevin McCormick , Christopher Boyce , Neng-Yang Shih , Chia-Yu Huang , Robert Aslanian , Jianhua Chao , Salem Fevrier , Bo Liang , Huagang Lu , Pietro Mangiaracina , Rong-Qiang Liu , Younong Yu
Inventor： Kevin McCormick , Christopher Boyce , Neng-Yang Shih , Chia-Yu Huang , Robert Aslanian , Jianhua Chao , Salem Fevrier , Bo Liang , Huagang Lu , Pietro Mangiaracina , Rong-Qiang Liu , Younong Yu
IPC: A61K31/4178 , A61K31/4709 , A61P1/12 , A61P13/00 , A61P25/00 , A61P25/06 , A61P25/18 , A61P25/24 , A61P27/14 , A61P37/00 , A61P9/00 , C07D215/00 , C07D403/06 , C12N5/00
CPC classification number: C07D403/02 , C07D401/14 , C07D403/06 , C07D405/14 , C07D407/14 , C07D409/14 , C07D413/14 , C07D417/14
Abstract: In its many embodiments, the present invention provides a novel class of indolines as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
Abstract translation: 在其许多实施方案中，本发明提供了作为α2C肾上腺素能受体激动剂抑制剂的新一类中和体，制备此类化合物的方法，含有一种或多种此类化合物的药物组合物，制备包含一种或多种此类化合物的药物制剂的方法，以及 使用这些化合物或药物组合物治疗，预防，抑制或改善与α2C肾上腺素能受体相关的一种或多种病症的方法。
-
Patent Agency Ranking
6.发明授权Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors 有权2,4-二氨基嘧啶作为ALK和c-Met抑制剂的稠合双环衍生物公开(公告)号：US08148391B2
公开(公告)日：2012-04-03
申请号：US12162851
申请日：2007-10-23
Applicant: Gulzar Ahmed , Henry Joseph Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph G. Lisko , Rong-Qiang Liu , Eugen Florin Mesaros , Karen Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho V. Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
Inventor： Gulzar Ahmed , Henry Joseph Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph G. Lisko , Rong-Qiang Liu , Eugen Florin Mesaros , Karen Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho V. Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
IPC: A61K31/505 , C07D239/02
CPC classification number: C07D239/48 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14
Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
Abstract translation: 本发明提供式I或II化合物或其药学上可接受的盐形式，其中R1，R2，R3，R4，R5，A1，A2，A3，A4和A5如本文所定义。 式I或II的化合物具有ALK和/或c-Met抑制活性，并且可用于治疗增殖性疾病。
-
公开(公告)号：US07700592B2
公开(公告)日：2010-04-20
申请号：US11705673
申请日：2007-02-13
Applicant: Kevin D. McCormick , Christopher W. Boyce , Neng-Yang Shih , Chia-Yu Huang , Robert G. Aslanian , Salem Fevrier , Bo Liang , Rong-qiang Liu , Ruiyan Liu , Pietro Mangiaracina , Manuel de Lera Ruiz , Younong Yu , Lisa Guise-Zawacki , Junying Zheng
Inventor： Kevin D. McCormick , Christopher W. Boyce , Neng-Yang Shih , Chia-Yu Huang , Robert G. Aslanian , Salem Fevrier , Bo Liang , Rong-qiang Liu , Ruiyan Liu , Pietro Mangiaracina , Manuel de Lera Ruiz , Younong Yu , Lisa Guise-Zawacki , Junying Zheng
IPC: C07D498/04 , A61K31/538
CPC classification number: C07D413/14 , C07D241/36 , C07D279/06 , C07D403/06 , C07D413/06 , C07D417/06 , C07D417/14 , C07D471/04 , C07D498/04
Abstract: In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as α2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the α2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.
Abstract translation: 在其许多实施方案中，本发明涉及可用作α2C肾上腺素能受体激动剂的新一类苯基吗啉和苯硫基吗啉化合物，含有该化合物的药物组合物，以及治疗，预防，抑制或改善一种或多种与 α2C肾上腺素能受体激动剂，使用这些化合物或药物组合物。
-
公开(公告)号：US20070099872A1
公开(公告)日：2007-05-03
申请号：US11508458
申请日：2006-08-23
Applicant: Kevin McCormick , Christopher Boyce , Robert Aslanian , Neng-Yang Shih , Salem Fevrier , Pietro Mangiaracina , Chia-Yu Huang , Bo Liang , Rong-Qiang Liu , Huagang Lu
Inventor： Kevin McCormick , Christopher Boyce , Robert Aslanian , Neng-Yang Shih , Salem Fevrier , Pietro Mangiaracina , Chia-Yu Huang , Bo Liang , Rong-Qiang Liu , Huagang Lu
IPC: A61K31/675 , A61K31/4709 , A61K31/4178 , C07D403/02
CPC classification number: C07D403/02 , C07D401/06 , C07D403/06
Abstract: In its many embodiments, the present invention provides a novel class of indolines as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
Abstract translation: 在其许多实施方案中，本发明提供了作为α2C肾上腺素能受体激动剂抑制剂的新一类中和体，制备此类化合物的方法，含有一种或多种此类化合物的药物组合物，制备包含一种或多种此类化合物的药物制剂的方法，以及 使用这些化合物或药物组合物治疗，预防，抑制或改善与α2C肾上腺素能受体相关的一种或多种病症的方法。
-
9.发明授权Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors 有权2,4-二氨基嘧啶作为ALK和c-MET抑制剂的稠合双环衍生物公开(公告)号：US08552186B2
公开(公告)日：2013-10-08
申请号：US13413322
申请日：2012-03-06
Applicant: Gulzar Ahmed , Henry J. Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce D. Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph Lisko , Rong-qiang Liu , Eugen F. Mesaros , Karen L. Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
Inventor： Gulzar Ahmed , Henry J. Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce D. Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph Lisko , Rong-qiang Liu , Eugen F. Mesaros , Karen L. Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
IPC: C07D403/12
CPC classification number: C07D239/48 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14
Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
Abstract translation: 本发明提供式I或II化合物或其药学上可接受的盐形式，其中R1，R2，R3，R4，R5，A1，A2，A3，A4和A5如本文所定义。 式I或II的化合物具有ALK和/或c-Met抑制活性，并且可用于治疗增殖性疾病。
-
10.发明申请Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors 有权2,4-二氨基嘧啶的双酚衍生物作为ALK和c-MET抑制剂公开(公告)号：US20120165519A1
公开(公告)日：2012-06-28
申请号：US13413322
申请日：2012-03-06
Applicant: Gulzar Ahmed , Henry Joseph Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph G. Lisko , Rong-qiang Liu , Eugen Mesaros , Karen Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho V. Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
Inventor： Gulzar Ahmed , Henry Joseph Breslin , Jason Burke , Matthew A. Curry , James L. Diebold , Bruce Dorsey , Benjamin J. Dugan , Daming Feng , Diane E. Gingrich , Tao Guo , Keith S. Learn , Joseph G. Lisko , Rong-qiang Liu , Eugen Mesaros , Karen Milkiewicz , Gregory R. Ott , Jay P. Theroff , Tho V. Thieu , Rabindranath Tripathy , Theodore L. Underiner , Gregory J. Wells , Craig A. Zificsak
IPC: C07D403/14 , C07D498/04 , C07D413/12 , C07D409/14 , C07D405/12 , C07D417/14 , C07D401/14 , C07D405/14 , C07D403/12 , C07D413/14
CPC classification number: C07D239/48 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14
Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
Abstract translation: 本发明提供式I或II化合物或其药学上可接受的盐形式，其中R1，R2，R3，R4，R5，A1，A2，A3，A4和A5如本文所定义。 式I或II的化合物具有ALK和/或c-Met抑制活性，并且可用于治疗增殖性疾病。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.067 seconds)
